Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Varubi Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Varubi (rolapitant) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for oral Varubi (rolapitant) used with other antiemetic agents to prevent delayed nausea and vomiting associated with emetogenic cancer chemotherapy. It applies to providers requesting coverage through Ventura County Health Care Plan.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyVarubi (rolapitant) Prior Authorization
    Policy CodePolicy N/A
    Change TypeClinical and safety updates
    Effective DateApr 23, 2019
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionDocument significant failure of alternative medications or submit a compelling reason to use Varubi as the primary therapeutic agent.
    SourceLink
    POLICY UPDATE CHANGES

    Precautions and clinically significant drug-interaction warnings were added to the Varubi authorization guidance.

    The policy revision history records numerous changes and additions to the Varubi guidance.

    180 mgRecommended single dose
    2 tabletsDrug quantity limit
    Day 1 onlyAdministration timing
    <2 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Contraindicated age
    CYP2D6 inhibitorInteraction classification

    Coverage Criteria

    Initial Varubi Authorization

    Covered when the indication requirement and one prerequisite for Varubi use are met.

    Varubi initial authorization

    • Prerequisite for Varubi use

      • Alternative-treatment failure: Significant failure of alternative medications is documented.

        Alternatives listed by the policy include ondansetron, metoclopramide, dexamethasone, olanzapine, promethazine, prochlorperazine, benzodiazepines, cannabinoids such as dronabinol or Marinol, ginger, and acupuncture.

      • Compelling clinical rationale: A compelling reason to use Varubi as the primary therapeutic agent is submitted by the requesting physician.

        The rationale must be submitted with the request.

    Administration and Quantity

    When approved, administer according to the specified regimen and quantity limit.

    Approved dosing regimen: Administer 180 mg as a single dose within 2 hours before chemotherapy begins on day 1 only, with dexamethasone on days 1 through 4 and a 5-HT3 receptor antagonist on day 1.180 mg single dose; within 2 hours before chemotherapy; day 1 only

    The available dosage form is a 90 mg tablet, and the quantity limit is 2 tablets per course.

    Intravenous Varubi has been discontinued in the United States. The policy applies to the oral tablet formulation.

    Avoid use of Varubi in patients with severe hepatic impairment.

    Avoid combining Varubi with thioridazine or pimozide because Varubi is a moderate CYP2D6 inhibitor and clinically significant drug interactions may occur.

    Provider Actions

    Prior Authorization

    Covered Chemotherapy-Related Indication

    Prior authorization is required for Varubi when used to prevent delayed nausea and vomiting associated with initial or repeat courses of emetogenic cancer chemotherapy, in combination with other antiemetic agents.

    Step Therapy

    Failure of Alternative Antiemetic Therapy

    Before approving Varubi, document a significant failure of alternative antiemetic therapy, unless a compelling clinical rationale supports its use as the primary therapeutic agent.

    • Alternative agents include ondansetron, metoclopramide, dexamethasone, olanzapine, promethazine, prochlorperazine, and benzodiazepines.
    Documentation Required

    Background

    Varubi (rolapitant) may be used alone or with other agents to prevent delayed nausea and vomiting associated with emetogenic chemotherapy. The policy expects Varubi to be used with dexamethasone and a 5-HT3 receptor antagonist as part of the chemotherapy antiemetic regimen.

    Definitions

    Varubi (rolapitant)
    MedicationVarubi (rolapitant)
    Drug classNeurokinin 1 (NK1) receptor antagonist
    Clinical useUsed alone or in combination with other agents to prevent delayed nausea and vomiting associated with emetogenic chemotherapy
    MechanismSelectively and competitively inhibits the substance P/neurokinin 1 (NK1) receptor
    Emetogenic cancer chemotherapy
    DefinitionChemotherapy associated with a clinically meaningful risk of causing nausea and vomiting
    Qualifying indication

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial authorization requires the covered chemotherapy-related indication and documentation supporting use of Varubi instead of alternatives.

    Initial therapy requirements

    • Covered indication: The patient is receiving an initial or repeat course of emetogenic cancer chemotherapy, and Varubi is requested in combination with other antiemetic agents.
    • Support for use of Varubi

      • Alternative-treatment failure: Significant failure of alternative medications is documented.
      • Compelling clinical rationale: A compelling reason to use Varubi as the primary therapeutic agent is submitted by the requesting physician.

    Step Therapy

    StepRequirementAlternative medications or rationale
    1Try alternative antiemetic therapy and document significant failure, or submit a compelling reason to use Varubi as the primary therapeutic agent.Ondansetron, metoclopramide, dexamethasone, olanzapine, promethazine, prochlorperazine, benzodiazepines, cannabinoids such as dronabinol/Marinol, ginger, or acupuncture.

    Quantity Limits

    Varubi (rolapitant) quantity limit
    Dosage formTablet: 90 mg
    Quantity limit2 tablets per course
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyVarubi (rolapitant) Prior Authorization
    Policy CodePolicy N/A
    Change TypeClinical and safety updates
    Effective DateApr 23, 2019
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionDocument significant failure of alternative medications or submit a compelling reason to use Varubi as the primary therapeutic agent.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaStep TherapyQuantity Limits

    Alternative-Treatment History or Compelling Rationale

    The requesting physician must submit documentation of the patient’s alternative-treatment history or a compelling reason to use Varubi as the primary therapeutic agent.

    • Alternative medicines that may be documented include cannabinoids such as dronabinol/Marinol, ginger, and acupuncture.
    Denial Risk

    Indication or Prerequisite Not Met

    Varubi may be denied when the covered chemotherapy-related indication is absent or when the required documentation of significant alternative-treatment failure or a compelling rationale is not provided.

    • Confirm use is for prevention of delayed nausea and vomiting associated with initial or repeat emetogenic chemotherapy.
    • Confirm combination use with other antiemetic agents.
    Denial Risk

    Safety or Interaction Concern

    Avoid or adjust Varubi use when safety concerns or clinically significant drug interactions are present. Varubi is a moderate CYP2D6 inhibitor and should not be used with thioridazine or pimozide.

    • Avoid use in patients with severe hepatic impairment.
    • Contraindicated in pediatric patients younger than 2 years of age.
    • Consult a drug-interaction database because additional dose, frequency, or avoidance decisions may be required.
    Billing Rule

    Oral Tablet Dosing Applies

    Because intravenous Varubi has been discontinued in the United States, use the oral tablet regimen when Varubi is authorized.

    • Dose: 180 mg as a single dose within 2 hours before chemotherapy on day 1 only.
    • Administer in combination with dexamethasone on days 1–4 and a 5-HT3 receptor antagonist on day 1.
    Prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy
    Combination requirementVarubi must be used in combination with other antiemetic agents